WW International (WW) Q2 2025 earnings summary

Executive summary

• Emerged from Chapter 11 bankruptcy on June 24, 2025, reducing debt from $1.6B to $465M and adopting fresh start accounting, with a reconstituted Board and relisting on NASDAQ.

• Strategic focus on innovation, operational excellence, and expansion into clinical and adjacent health offerings, including women's health.

• Leadership team strengthened with new hires in key roles, including Chief Experience Officer and Chief Medical Officer.

• Q2 2025 combined revenues were $189M, down 6% year-over-year; Clinical revenues grew 55% while Behavioral declined 13%.

• ARPU increased 12% year-over-year, driven by a higher Clinical mix.

Financial highlights

• Debt reduced from $1.6B to $465M; lenders and noteholders now hold 91% of new equity.

• Q2 2025 revenue: $189.2M (combined), down 6.1% year-over-year; Clinical revenue $31M, up 55% year-over-year.

• Net income: $1.3M (Successor), $1,191M (Predecessor), driven by reorganization gains.

• Adjusted EBITDA margin: 34% (Predecessor), 37% (Successor), up over 900 bps year-over-year.

• Ended Q2 with $152M in cash and cash equivalents, down from $236M in Q1, mainly due to reorganization costs.

Outlook and guidance

• FY2025 guidance: total combined revenues of $685M–$700M and adjusted EBITDA of $140M–$150M.

• Expect continued revenue headwinds from lower subscriber levels and challenging acquisition environment, but long-term growth opportunity remains significant.

• Depreciation and amortization expected to be ~$50M in H2 2025 due to fresh start accounting.